Replies to post #247207 on Biotech Values

[DewDiligence]

RAIN acquired by private-equity firm for $1.16/sh cash +CVR. Excluding the CVR, the buyout price is a 17% premium to the unaffected share price on 10/13/23, but a discount to RAIN’s net cash per share (!):

https://www.globenewswire.com/news-release/2023/12/13/2795922/0/en/Rain-Oncology-Enters-into-Agreement-to-be-Acquired-by-Pathos-AI-for-1-16-in-Cash-per-Share-Plus-Contingent-Value-Rights.html